| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | L-赖氨酸羟化酶和利用了该L-赖氨酸羟化酶的羟基-L-赖氨酸的制造法及羟基-L-2-哌啶酸的制造法 | CN201480002505.X | 2014-02-18 | CN104685061A | 2015-06-03 | 木野邦器; 原良太郎; 三宅良磨; 川端润 |
| 本发明的课题在于提供一种能够有效地制造羟基-L-赖氨酸的方法。本发明提供一种羟基-L-赖氨酸的制造方法，其特征在于，使2-酮戊二酸依赖型L-赖氨酸羟化酶或包含该2-酮戊二酸依赖型L-赖氨酸羟化酶的细胞、所述细胞的制备物或者对所述细胞进行培养而得到的培养液与L-赖氨酸作用，生成下述通式(I)(式中，R1、R2和R3分别表示氢原子或羟基，R1、R2和R3中的至少一个表示羟基)所表示的羟基-L-赖氨酸。 | ||||||
| 2 | Ｌ−リジン水酸化酵素およびそれを利用したヒドロキシ−Ｌ−リジンの製造法およびヒドロキシ−Ｌ−ピペコリン酸の製造法 | JP2015501458 | 2014-02-18 | JPWO2014129459A1 | 2017-02-02 | 木野 邦器; 邦器 木野; 良太郎 原; 良磨 三宅; 潤 川端 |
| 効率よくヒドロキシ-L-リジンを製造できる方法を提供することを課題とする。本発明は、L-リジンに2-オキソグルタル酸依存型L-リジン水酸化酵素またはそれを含む細胞、前記細胞の調製物もしくは前記細胞を培養して得られた培養液を作用させて、下記一般式(I)(式中、R1、R2およびR3はそれぞれ水素原子もしくはヒドロキシル基を示し、R1、R2およびR3の少なくとも一つはヒドロキシル基を示す)で表されるヒドロキシ-L-リジンを生成させることを特徴とする、ヒドロキシ-L-リジンの製造方法を提供する。 | ||||||
| 3 | グリシン繰り返し配列タンパク質を産生する形質転換体 | JP2012505681 | 2011-03-14 | JPWO2011115070A1 | 2013-06-27 | 昌一 西尾 |
| 下記(1)〜(3)の全てのタンパク質のアミノ酸配列をコードする塩基配列を有するポリヌクレオチドが微生物細胞内に導入されて得られることを特徴とする形質転換体等。(1)FK506に結合性を有し、且つ、分子量1万5千以上、6万以下であるFK506タンパク質(2)プロリン水酸化酵素(3)下記の特性(A)及び(B)を有するグリシン繰り返し配列タンパク質<特性(A)>グリシン繰り返し配列タンパク質におけるポリペプチド鎖が、連続するGly−Xaa−Yaaの繰り返し配列を有する。<特性(B)>グリシン繰り返し配列タンパク質におけるポリペプチド鎖の連続するGly−Xaa−Yaaの繰り返し配列にイミノ酸が含まれている。 | ||||||
| 4 | Transformant producing collagen in which both lysine residue and proline residue are hydroxylated | JP2010252606 | 2010-11-11 | JP2011120576A | 2011-06-23 | NISHIO SHOICHI |
| <P>PROBLEM TO BE SOLVED: To find out collagen capable of becoming a high performance raw material for multiple uses, and having further value commercially such as pharmaceuticals, industrial products, cosmetics, foods, etc., (concretely, e.g. the collagen in which triple helical structure is stabilized, and also has a high fiber-forming property) and a method for obtaining such the found out new collagen. <P>SOLUTION: The transformants, etc., are obtained by introducing, into the cells of microorganisms, a foreign gene having base sequences encoding the amino acid sequences of whole of the proteins of the following (1) to (3), including (1) Lysine hydroxylase, (2) proline hydroxylase, and (3) collagen. <P>COPYRIGHT: (C)2011,JPO&INPIT | ||||||
| 5 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN | US16177153 | 2018-10-31 | US20190160122A1 | 2019-05-30 | Suma Krishnan; Pooja Agarwal |
| The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa. | ||||||
| 6 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF WOUNDS, DISORDERS, AND DISEASES OF THE SKIN | US15851488 | 2017-12-21 | US20180169160A1 | 2018-06-21 | Suma Krishnan; Pooja Agarwal |
| The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa. | ||||||
| 7 | PLOD2 as a Target of Intervention for Sarcoma Metastasis | US14287752 | 2014-05-27 | US20140356287A1 | 2014-12-04 | M. Celeste Simon; T.S. Karin Eisinger |
| The invention provides compositions and methods for treating a disease or disorder by lowering the level of PLOD2 in a subject. | ||||||
| 8 | COLLAGEN PRODUCING PLANTS AND METHODS OF GENERATING AND USING SAME | US13936274 | 2013-07-08 | US20130289243A1 | 2013-10-31 | Oded SHOSEYOV; Hanan Stein |
| A method of producing collagen in a plant and plants producing collagen are provided. The method is effected by expressing in the plant at least one type of a collagen alpha chain in a manner enabling accumulation of the collagen alpha chain in a subcellular compartment devoid of endogenous P4H activity, thereby producing the collagen in the plant. | ||||||
| 9 | COLLAGEN PRODUCING PLANTS AND METHODS OF GENERATING AND USING SAME | US13541880 | 2012-07-05 | US20120284817A1 | 2012-11-08 | Oded SHOSEYOV; Hanan Stein |
| A method of producing collagen in a plant and plants producing collagen are provided. The method is effected by expressing in the plant at least one type of a collagen alpha chain in a manner enabling accumulation of the collagen alpha chain in a subcellular compartment devoid of endogenous P4H activity, thereby producing the collagen in the plant. | ||||||
| 10 | Methods for reducing or preventing localized fibrosis using SiRNA | US11183486 | 2005-07-18 | US20060030538A1 | 2006-02-09 | Marc Hendriks |
| Methods for reducing or preventing localized fibrosis in a localized tissue region using SiRNA technology. | ||||||
| 11 | COMPOUNDS BINDING TO JMJD6 WITH ANTIFIBROTIC ACTIVITY | US15553642 | 2016-02-26 | US20180044433A1 | 2018-02-15 | Mario Paolo Colombo; Silvia Miotti; Elda Tagliabue; Sabina Sangaletti |
| The present invention relates to the interaction between JMJD6 protein and collagen and to the possibility of inhibiting this interaction for the prevention and treatment of fibrosis and of tumor metastases. The invention further relates to a compound that is able to block the interaction between collagen and JMJD6 protein, in particular the invention relates to a new monoclonal antibody that recognizes JMJD6 and is able to block this interaction. | ||||||
| 12 | Compositions and methods for the treatment of wounds, disorders, and diseases of the skin | US15393151 | 2016-12-28 | US09877990B2 | 2018-01-30 | Suma Krishnan; Pooja Agarwal |
| The present disclosure relates, in part, to pharmaceutical compositions comprising one or more polynucleotides suitable for enhancing, increasing, augmenting, and/or supplementing the levels of Collagen alpha-1 (VII) chain polypeptide and/or Lysyl hydroxylase 3 polypeptide and/or Keratin type I cytoskeletal 17 polypeptide in a subject. The present disclosure also relates, in part, to pharmaceutical compositions and methods of use for providing prophylactic, palliative, or therapeutic relief of a wound, disorder, or disease of the skin in a subject, including a subject having, or at risk of developing, one or more symptoms of epidermolysis bullosa. | ||||||
| 13 | TREATMENT OF SKIN DISORDERS | US14379169 | 2013-02-14 | US20150352191A1 | 2015-12-10 | Andrew South; Stephen Watt; Irene Leigh |
| The present invention is based upon the finding that certain conditions, diseases and/or disorders affecting the skin, are associated with reduced expression of an enzyme exhibiting oxidoreductase activity. Accordingly, the invention provides oxidoreductase enzymes and/or genes encoding the same for use in treating or preventing disorders of the skin and method for generating Type VII collagen suitable for use in treating disorders of the skin. | ||||||
| 14 | Collagen producing plants and methods of generating and using same | US11730071 | 2007-03-29 | US08455717B2 | 2013-06-04 | Oded Shoseyov; Hanan Stein |
| A method of producing collagen in a plant and plants producing collagen are provided. The method is effected by expressing in the plant at least one type of a collagen alpha chain in a manner enabling accumulation of the collagen alpha chain in a subcellular compartment devoid of endogenous P4H activity, thereby producing the collagen in the plant. | ||||||
| 15 | Pharmaceutical product | US12589882 | 2009-10-29 | US20100124548A1 | 2010-05-20 | Raili Myllylä; Heli Ruoisalainen |
| The present invention relates to methods and products for the treatment of any disorder or condition, which is associated with abnormal amount of non-collagenous protein, or abnormal oligomerization or dysfunction of non-collagenous protein, such as adiponectin in the blood circulation and/or tissue of a patient. The treatment comprises that functional form of the non-collagenous protein is adjusted in the blood circulation and/or tissue of the patient substantially to the level it is in the blood circulation and/or tissue of a healthy person, by using lysyl hydroxylase and/or glycosyl-transferase activities of LH3 or other lysyl hydroxylase to modify the non-collagenous protein to HMW or other functional form. | ||||||
| 16 | Sequences characteristic of hypoxia-regulated gene transcription | US11440016 | 2006-05-25 | US20060241290A1 | 2006-10-26 | Paz Einat; Rami Skaliter; Elena Feinstein; Aviv Regev |
| There are provided polynucleotides that are modulated by hypoxic conditions. The disclosure includes such genes and proteins as well as analogs, salts and functional derivatives of such proteins, and DNA encoding such analogs, and methods of use. Methods for treating the effects of stroke, hypoxia and/or ischemia by regulating such genes or proteins are also disclosed. The presence of hypoxia or a hypoxia-associated pathology may be diagnosed by screening for the presence of at least one polynucleotide having the nucleic acid sequence according to the present invention. Methods of regulating hypoxia associated pathologies are also provided. | ||||||
| 17 | PRODUCTION METHOD FOR L-LYSINE HYDROXYLASE AND HYDROXY-L-LYSINE USING SAME, AND PRODUCTION METHOD FOR HYDROXY-L-PIPECOLIC ACID | EP14754464.7 | 2014-02-18 | EP2889378A1 | 2015-07-01 | KINO, Kuniki; HARA, Ryotaro; MIYAKE, Ryoma; KAWABATA, Hiroshi |
The present invention aims to provide a method for efficiently producing hydroxy-L-lysine. The present invention provides a method for producing hydroxy-L-lysine, the method comprising allowing 2-oxoglutarate-dependent L-lysine hydroxylase, a cell containing 2-oxoglutarate-dependent L-lysine hydroxylase, a processed product of the cell, and/or a culture broth obtained by culturing the cell, to act on L-lysine to produce hydroxy-L-lysine represented by the following General Formula (I) (wherein each of R1, R2 and R3 represents a hydrogen atom or hydroxyl group, with the proviso that at least one of R1, R2 and R3 represents a hydroxyl group).
|
||||||
| 18 | TRANSFORMANT WHICH PRODUCES GLYCINE REPEAT PROTEIN | EP11756255.3 | 2011-03-14 | EP2548947A1 | 2013-01-23 | NISHIO, Shoichi |
Disclosed is a transformant in which polynucleotides comprising a nucleotide sequence encoding the amino acid sequence of all of the following proteins (1) to (3) are transfected into a microbial cell: |
||||||
| 19 | TRANSFORMANT WHICH PRODUCES COLLAGEN WHEREIN BOTH LYSINE RESIDUE AND PROLINE RESIDUE ARE HYDROXYLATED | EP10830048.4 | 2010-11-16 | EP2502991A1 | 2012-09-26 | NISHIO, Shoichi |
Disclosed is a transformant in which all of the foreign genes (1)-(3)described below are transfected into a microbial cell in order to obtain collagen that can be a high-performance versatile material which is commercially more valuable as a pharmaceutical product, industrial product, cosmetic product, food and the like. (1) A foreign gene comprising a nucleotide sequence encoding the amino acid sequence of lysyl hydroxylase (2) A foreign gene comprising a nucleotide sequence encoding the amino acid sequence of prolyl hydroxylase (3) A foreign gene comprising a nucleotide sequence encoding the amino acid sequence of collagen. |
||||||
| 20 | METHODS FOR REDUCING OR PREVENTING LOCALIZED FIBROSIS USING SiRNA | EP05772309.0 | 2005-07-18 | EP1773993A2 | 2007-04-18 | HENDRIKS, Marc |
| Methods for reducing or preventing localized fibrosis in a localized tissue region using SiRNA technology. | ||||||
QQ群二维码
意见反馈
意见反馈